JO3170B1 - مركبات و تراكيب لتثبيت parp و طرق استعمالها - Google Patents

مركبات و تراكيب لتثبيت parp و طرق استعمالها

Info

Publication number
JO3170B1
JO3170B1 JOP/2008/0433A JOP20080433A JO3170B1 JO 3170 B1 JO3170 B1 JO 3170B1 JO P20080433 A JOP20080433 A JO P20080433A JO 3170 B1 JO3170 B1 JO 3170B1
Authority
JO
Jordan
Prior art keywords
inhibitor compounds
relates
parp inhibitor
compounds
disclosed
Prior art date
Application number
JOP/2008/0433A
Other languages
English (en)
Inventor
Zhang Jie
Delahanty Greg
Wei Ling
Xu Weizheng
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40526672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3170(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Inc filed Critical Eisai Inc
Application granted granted Critical
Publication of JO3170B1 publication Critical patent/JO3170B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الراهن بمركبات رابع ازاز فنالين -3- ون تثبط انزيم بولي( ADP- ribose) بوليميراز ( PARP) وهي مفيدة في ا لاحساس الكيميائي لعقاقير علاج السرطان، يعتبر حث المرض العصبي المحيطي من التاثيرات الجانبية الشائعه في العددي من عقاقير العلاج الكيميائي التقليدية والجديدة، والاختراع الراهن يكفل وسائل لمنع او علاج المرض العصبي المحفز بالعلاج الكيميائي بكفاءه، ويتعلق الاختراع كذلك باستعمال مركبات تثبيط PARP موضوع الاختراع في تعزيز كفاءه عوامل العلاج الكيميائي مثل تيموزواوميد، ويتعلق الاختراع كذلك باستعمال مركبات تثبيط PARP موضوع الاختراع في الخلايا الحساسة للاشعاع وذلك لتاين الاشعاع، ويتعلق الاختراع كذلك باستعمال مركبات تثبيط PARP موضوع الاختراع في علاج السرطان الذي يتميز بعيوب اصلاح DNA .
JOP/2008/0433A 2007-10-03 2008-10-05 مركبات و تراكيب لتثبيت parp و طرق استعمالها JO3170B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97711507P 2007-10-03 2007-10-03

Publications (1)

Publication Number Publication Date
JO3170B1 true JO3170B1 (ar) 2017-09-20

Family

ID=40526672

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2008/0433A JO3170B1 (ar) 2007-10-03 2008-10-05 مركبات و تراكيب لتثبيت parp و طرق استعمالها

Country Status (27)

Country Link
US (3) US8236802B2 (ar)
EP (2) EP2209375B1 (ar)
JP (1) JP5439380B2 (ar)
KR (1) KR101596526B1 (ar)
CN (1) CN102083314B (ar)
AU (1) AU2008308664B2 (ar)
BR (1) BRPI0820518B1 (ar)
CA (1) CA2700903C (ar)
CL (1) CL2010000320A1 (ar)
CY (1) CY1115747T1 (ar)
DK (1) DK2209375T3 (ar)
ES (1) ES2504690T3 (ar)
HR (1) HRP20140853T1 (ar)
IL (1) IL204776A (ar)
JO (1) JO3170B1 (ar)
MX (1) MX2010003564A (ar)
MY (1) MY155237A (ar)
NZ (1) NZ585012A (ar)
PL (1) PL2209375T3 (ar)
PT (1) PT2209375E (ar)
RU (1) RU2485122C2 (ar)
SG (1) SG185272A1 (ar)
SI (1) SI2209375T1 (ar)
TW (1) TWI426912B (ar)
UA (1) UA99483C2 (ar)
WO (1) WO2009046205A1 (ar)
ZA (1) ZA201002317B (ar)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820668B2 (en) 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
ES2504690T3 (es) 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
CN104478875B (zh) * 2008-08-06 2017-04-12 麦迪韦逊科技有限公司 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
EP2322658A1 (en) 2009-11-13 2011-05-18 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of breast cancer aggressiveness and genetic instability
KR101826652B1 (ko) * 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
EP3012329B1 (en) 2010-06-18 2017-10-25 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
US9359605B2 (en) * 2011-03-11 2016-06-07 Sarissa Inc. Method of treating cancer by inhibition of DNA repair proteins
SG2014014294A (en) * 2011-04-11 2014-06-27 Abbvie Inc Parp inhibitors for the treatment of cipn
EP2710142B1 (en) 2011-05-18 2017-04-26 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of cancer aggressiveness and genetic instability
EP2731942B1 (en) * 2011-07-13 2015-09-23 Novartis AG Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
BR112014015152A2 (pt) * 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
EP2800821B1 (en) 2012-01-05 2016-11-16 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of lung cancer aggressiveness
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
CN104945406B (zh) * 2015-05-25 2017-10-10 苏州康润医药有限公司 氮杂非那烯‑3‑酮的衍生物、其制备方法及其作为parp抑制剂的应用
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
US12121518B2 (en) * 2017-03-09 2024-10-22 The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College PARP-1 and methods of use thereof
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
AU2019373416A1 (en) 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
US12479830B2 (en) * 2019-10-10 2025-11-25 Esteve Pharmaceuticals, S.A. Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021249996A1 (en) 2020-06-08 2021-12-16 Oncology Venture ApS Compositions comprising 2x-121 and methods for treating coronavirus infection
CN114053276B (zh) * 2020-07-30 2024-05-07 江苏天士力帝益药业有限公司 一种parp抑制剂tsl-1502中间体tsl-1502m的用途
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US5950784A (en) 1997-09-03 1999-09-14 Yang; Shu-Chiung C. Hub structural improvement
CA2332279A1 (en) 1998-05-15 1999-11-25 Jia-He Li Carboxamide compounds, compositions, and methods for inhibiting parp activity
AU9298798A (en) 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
DE50112961D1 (de) 2000-02-01 2007-10-18 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
ES2396334T3 (es) 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
JP2006527235A (ja) * 2003-06-10 2006-11-30 エフ．ホフマン−ラ　ロシュ　アーゲー １，３，４−トリアザフェナレンおよび１，３，４，６−テトラアザフェナレン誘導体
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
PL2305221T3 (pl) 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
DE602005011308D1 (de) 2004-08-04 2009-01-08 Phosphonics Ltd Substituierte organopolysiloxane und ihre verwendung
US7820668B2 (en) 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
ES2504690T3 (es) 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
US7981887B2 (en) 2008-05-09 2011-07-19 Allergan, Inc. Therapeutic compounds
JP2013531007A (ja) 2010-07-08 2013-08-01 ワイス・エルエルシー 皮膚障害の治療に有用な新規キノリンエステル

Also Published As

Publication number Publication date
TW200932239A (en) 2009-08-01
US8236802B2 (en) 2012-08-07
AU2008308664A1 (en) 2009-04-09
ES2504690T3 (es) 2014-10-08
CA2700903A1 (en) 2009-04-09
AU2008308664B2 (en) 2014-07-17
EP2209375A1 (en) 2010-07-28
PL2209375T3 (pl) 2014-12-31
BRPI0820518A2 (pt) 2020-01-14
JP5439380B2 (ja) 2014-03-12
ZA201002317B (en) 2013-09-25
RU2485122C2 (ru) 2013-06-20
US8894989B2 (en) 2014-11-25
KR101596526B1 (ko) 2016-02-22
EP2209375B1 (en) 2014-08-27
CY1115747T1 (el) 2017-01-25
EP2842956A1 (en) 2015-03-04
DK2209375T3 (da) 2014-10-06
IL204776A (en) 2015-09-24
CN102083314B (zh) 2014-04-30
RU2010117397A (ru) 2011-11-10
JP2010540655A (ja) 2010-12-24
HRP20140853T1 (hr) 2014-10-24
IL204776A0 (en) 2010-11-30
US20150141429A1 (en) 2015-05-21
UA99483C2 (ru) 2012-08-27
BRPI0820518B1 (pt) 2021-09-28
KR20100100771A (ko) 2010-09-15
MY155237A (en) 2015-09-30
US20130011365A1 (en) 2013-01-10
SG185272A1 (en) 2012-11-29
NZ585012A (en) 2012-06-29
US20090098084A1 (en) 2009-04-16
HK1146792A1 (en) 2011-07-15
CL2010000320A1 (es) 2011-03-11
CN102083314A (zh) 2011-06-01
CA2700903C (en) 2017-05-30
TWI426912B (zh) 2014-02-21
MX2010003564A (es) 2010-09-10
EP2209375A4 (en) 2011-03-09
WO2009046205A1 (en) 2009-04-09
PT2209375E (pt) 2014-10-08
SI2209375T1 (sl) 2014-12-31

Similar Documents

Publication Publication Date Title
JO3170B1 (ar) مركبات و تراكيب لتثبيت parp و طرق استعمالها
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
EP2298304A3 (en) Carboline derivatives useful in the treatment of cancer
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
NZ584042A (en) Use of mva to treat prostate cancer
SG164368A1 (en) Treatment of cancer
CL2011001863A1 (es) Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07).
IN2012DN01964A (ar)
WO2008076278A8 (en) Methods of cancer treatment with igf1r inhibitors
MX2010006154A (es) Tratamiento del cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de la poli-adp-ribosa-polimerasa.
PE20070496A1 (es) Compuestos derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina
WO2005094376A3 (en) Synergistic methods and compositions for treating cancer
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
MX2009005300A (es) Combinacion de un inhibidor de acido desoxirribonucleico polimerasa-alfa y un inhibidor de una cinasa de punto de verificacion para trastornos proliferativos.
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
WO2007129226A3 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
MX2011009033A (es) Inhibidores triciclicos de cinasa pirazolopiridina.
CR10450A (es) Metodo para inhibir la cinasa del c-kit
WO2011056566A3 (en) Compounds and methods for treatment of cancer
WO2008033887A8 (en) Methods for treating cancer